28 completed, 6 terminated, 5 unknown, 2 active not recruiting. 45 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 45 | Completed 28, Terminated 6, Unknown 5, Active not recruiting 2, Recruiting 2, Withdrawn 2 |
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate MAR002 for Acromegaly MAR002, Placebo - Acromegaly | Phase 2 | Recruiting | Marea Therapeutics | 72 | 2026-07-23 | 2026-09-11 |
| ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly ALXN2420, Placebo - Acromegaly | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2025-10-28 | 2026-08-07 |
| Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease Vorinostat - Cushing's Disease | Phase 2 | Withdrawn | National Institute of Neurological Disorders and Stroke (NINDS) | 2025-04-11 | 2025-04-15 | |
| Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease Fimepinostat - Cushing Disease | Phase 2 | Recruiting | University of California, Los Angeles | 20 | 2025-01-16 | 2026-07-17 |
| A Trial of Lu AG13909 in Adult Participants With Cushing's Disease Lu AG13909 - Cushing's Disease | Phase 2 | Active not recruiting | H. Lundbeck A/S | 16 | 2024-06-19 | 2026-10-16 |
| A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly SYHX2008, Sandostatin LAR - Acromegaly | Phase 2 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 78 | 2024-04-16 | 2026-09-11 |
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome atumelnant - Cushing Syndrome, Cushing Disease | Phase 1 / Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 19 | 2023-10-12 | 2026-10-14 |
| SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome SPI-62, Placebo - Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion | Phase 2 | Completed | Sparrow Pharmaceuticals | 26 | 2022-09-01 | 2025-10-08 |
| A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly GHR-LRX - Acromegaly | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 34 | 2021-01-04 | 2024-10-03 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) Paltusotine - Acromegaly | Phase 2 | Terminated | Crinetics Pharmaceuticals Inc. | 43 | 2020-01-29 | 2026-07-29 |
| Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands IONIS GHR-LRx, Somatostatin Receptor Ligand (SRL) - Acromegaly | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 39 | 2019-07-25 | 2023-03-22 |
| An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) Paltusotine - Acromegaly | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 47 | 2019-03-12 | 2025-02-17 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) Paltusotine, Placebo - Acromegaly | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 13 | 2019-03-11 | 2025-03-17 |
| Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo, control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo - Anovulatory Infertility, Abnormal Uterine Bleeding-Ovulatory Disorders | Phase 2 | Unknown | Xiyuan Hospital of China Academy of Chinese Medical Sciences | 528 | 2019-02-01 | 2019-01-10 |
| Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Seliciclib - Cushing Disease | Phase 2 | Completed | Cedars-Sinai Medical Center | 5 | 2018-11-02 | 2026-10-16 |
| Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands IONIS-GHR-LRx, Placebo - Acromegaly | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 43 | 2018-09-13 | 2022-11-14 |
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome relacorilant - Cushing Syndrome | Phase 2 | Active not recruiting | Corcept Therapeutics | 125 | 2018-05-07 | 2026-11-03 |
| Administration of Kisspeptin in Patients With Hyperprolactinemia Kisspeptin 112-121, GnRH - Hyperprolactinemia, Hypogonadism | Phase 2 | Completed | Massachusetts General Hospital | 36 | 2017-11-17 | 2024-10-01 |
| Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly BIM23B065 - Acromegaly | Phase 2 | Terminated | Ipsen | 4 | 2017-01-26 | 2019-03-08 |
| Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Ropinirole - Hyperprolactinemia, Prolactinoma | Phase 1 / Phase 2 | Completed | Columbia University | 16 | 2016-09-16 | 2024-06-04 |
Showing 20 of 45. Sign in to see all of them.
Acromegaly (27) · Pituitary ACTH Hypersecretion (14) · ACTH Syndrome, Ectopic (4) · Cushing Syndrome (4) · Hyperprolactinemia (4) · Pituitary Neoplasms (3) · Adrenal Cortex Neoplasms (2) · Adrenocortical Carcinoma (2) · Adrenocortical Hyperfunction (2) · Diabetes Mellitus, Type 2 (2) · Hypertension (2) · Gigantism (1) · Growth Disorders (1) · Hypertrophy, Left Ventricular (1) · Hypogonadism (1)
Brain Diseases (45) · Central Nervous System Diseases (45) · Endocrine System Diseases (45) · Hypothalamic Diseases (45) · Nervous System Diseases (45) · Pituitary Diseases (44) · Bone Diseases (27) · Bone Diseases, Endocrine (27) · Musculoskeletal Diseases (27) · Neoplasms (10) · Adrenal Gland Diseases (6) · Endocrine Gland Neoplasms (6) · Neoplasms by Site (6) · Adrenocortical Hyperfunction (4)
Octreotide (6) · pasireotide (5) · lanreotide (4) · Clomiphene (2) · PTR 3173 (2) · relacorilant (2) · BIM23B065 (1) · Bexarotene (1) · Cabergoline (1) · Ethinyl Estradiol-Norgestrel Combination (1) · Gefitinib (1) · Gonadotropin-Releasing Hormone (1) · Osilodrostat (1) · Roscovitine (1) · Rosiglitazone (1)
Novartis Pharmaceuticals (6) · Ipsen (5) · Crinetics Pharmaceuticals Inc. (4) · Ionis Pharmaceuticals, Inc. (3) · Aspireo Pharmaceuticals Limited (2) · Corcept Therapeutics (2) · Alexion Pharmaceuticals, Inc. (1) · Andrea M. Isidori (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Camurus AB (1) · Cedars-Sinai Medical Center (1) · Columbia University (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Felipe Henning Gaia Duarte (1) · H. Lundbeck A/S (1)
United States (28) · Italy (14) · Hungary (12) · France (10) · Poland (10) · Romania (10) · Germany (9) · Serbia (8) · Netherlands (7) · United Kingdom (7) · Lithuania (6) · Belgium (5) · Brazil (5) · Spain (5) · China (4)
Andreas G Moraitis, MD (1) · Anthony Heaney, MD (1) · Elisa Giannetta, MD - Phd (1) · Frank Czerwiec, MD (1) · Gabrielle Page-Wilson, M.D. (1) · Hai-jun Wang, MD (1) · John McNally (1) · Kun Ma, Dr. (1) · Marcello D Bronstein, MD, PhD (1) · Marianne Pavel, Professor (1) · Mary Lee Vance, MD (1)
PMID 36792844, PMID 19639415, PMID 20061334, PMID 20410233, PMID 21138567, PMID 23529827, PMID 23943009, PMID 24423285, PMID 27755159, PMID 30535537, PMID 32524605, PMID 34335465, PMID 34664531, PMID 35058882, PMID 35804385, PMID 37715962, PMID 37876540, PMID 41052284
2004 (2), 2015 (2), 2018 (2), 2019 (2), 2009 (1), 2014 (1), 2017 (1), 2023 (1), R21DK112093 (1)